Merck & Co’s CEO Ken Frazier has received the strongest possible backing from the company’s board, after it was announced the pharma company has rescinded a mandatory retirement age pol
Roche is eyeing a new use for its checkpoint inhibitor immunotherapy Tecentriq after it posted results showing it extended patients’ lives by an extra two months compared with chemotherapy
The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was previously only treatable with chemotherapy.
Australian biotech Immutep has begun a clinical trial partnership with Germany’s Merck KGaA and Pfizer to develop a new cancer immunotherapy combination therapy.
Roche has launched a blood test that can identify 70 of the most commonly mutated genes in solid tumours, as the company seeks to make more medicine more personalised.
Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use whe